Search Results - "Laskin, J"

Chemical characterization of SOA formed from aqueous-phase reactions of phenols with the triplet excited state of carbonyl and hydroxyl radical by Yu, L, Smith, J, Laskin, A, Anastasio, C, Laskin, J, Zhang, Q

“…Phenolic compounds, which are emitted in significant amounts from biomass burning, can undergo fast reactions in atmospheric aqueous phases to form secondary…”
Get full text

Association between walking 5000 step/day and fall incidence over six months in urban community-dwelling older people by Aranyavalai, T, Jalayondeja, C, Jalayondeja, W, Pichaiyongwongdee, S, Kaewkungwal, J, Laskin, J J

“…Walking is the most common population-wide campaign for health promotion in older people. However, the cutoff threshold for walking steps/day to identify the…”
Get full text

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis by Papadimitrakopoulou, V.A., Mok, T.S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S.S., Kim, S.W., Shepherd, F.A., Laskin, J., He, Y., Akamatsu, H., Theelen, W.S.M.E., Su, W.-C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., Wu, Y.-L.

“…In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged…”
Get full text

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial by Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K.H., Lu, S., Shi, Y., Lee, D.H., Laskin, J., Kim, D.-W., Laurie, S.A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.

“…In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and…”
Get full text

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents by Laskin, J., Liu, S.V., Tolba, K., Heining, C., Schlenk, R.F., Cheema, P., Cadranel, J., Jones, M.R., Drilon, A., Cseh, A., Gyorffy, S., Solca, F., Duruisseaux, M.

“…Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to deregulated activity. Fusions involving the neuregulin-1…”
Get full text

Effect of humidity on the composition of isoprene photooxidation secondary organic aerosol by Nguyen, T. B., Roach, P. J., Laskin, J., Laskin, A., Nizkorodov, S. A.

“…The effect of relative humidity (RH) on the composition and concentrations of gas-phase products and secondary organic aerosol (SOA) generated from the…”
Get full text

Whole genome and transcriptome analysis enhances precision cancer treatment options by Pleasance, E., Bohm, A., Williamson, L.M., Nelson, J.M.T., Shen, Y., Bonakdar, M., Titmuss, E., Csizmok, V., Wee, K., Hosseinzadeh, S., Grisdale, C.J., Reisle, C., Taylor, G.A., Lewis, E., Jones, M.R., Bleile, D., Sadeghi, S., Zhang, W., Davies, A., Pellegrini, B., Wong, T., Bowlby, R., Chan, S.K., Mungall, K.L., Chuah, E., Mungall, A.J., Moore, R.A., Zhao, Y., Deol, B., Fisic, A., Fok, A., Regier, D.A., Weymann, D., Schaeffer, D.F., Young, S., Yip, S., Schrader, K., Levasseur, N., Taylor, S.K., Feng, X., Tinker, A., Savage, K.J., Chia, S., Gelmon, K., Sun, S., Lim, H., Renouf, D.J., Jones, S.J.M., Marra, M.A., Laskin, J.

“…Recent advances are enabling delivery of precision genomic medicine to cancer clinics. While the majority of approaches profile panels of selected genes or…”
Get full text

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer by Jones, M.R., Lim, H., Shen, Y., Pleasance, E., Ch'ng, C., Reisle, C., Leelakumari, S., Zhao, C., Yip, S., Ho, J., Zhong, E., Ng, T., Ionescu, D., Schaeffer, D.F., Mungall, A.J., Mungall, K.L., Zhao, Y., Moore, R.A., Ma, Y., Chia, S., Ho, C., Renouf, D.J., Gelmon, K., Jones, S.J.M., Marra, M.A., Laskin, J.

“…NRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer, but clinical support is currently limited and no evidence of…”
Get full text

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer by Jimeno, A., Shirai, K., Choi, M., Laskin, J., Kochenderfer, M., Spira, A., Cline-Burkhardt, V., Winquist, E., Hausman, D., Walker, L., Cohen, R.B.

“…This manuscript reports on a prospective, randomized study of cetuximab plus/minus a small molecule PI3K inhibitor (PX-866) targeting the protein product of…”
Get full text

Combined neuromuscular electrical stimulation with motor control exercise can improve lumbar multifidus activation in individuals with recurrent low back pain by Songjaroen, Sranya, Sungnak, Panakorn, Piriyaprasarth, Pagamas, Wang, Hsing-Kuo, Laskin, James J., Wattananon, Peemongkon

“…Motor control exercise (MCE) is commonly prescribed for patients with low back pain. Although MCE can improve clinical outcomes, lumbar multifidus muscle (LM)…”
Get full text

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study by Titmuss, E, Milne, K, Jones, M R, Ng, T, Topham, J T, Brown, S D, Schaeffer, D F, Kalloger, S, Wilson, D, Corbett, R D, Williamson, L M, Mungall, K, Mungall, A J, Holt, R A, Nelson, B H, Jones, S J M, Laskin, J, Lim, H J, Marra, M A

“…Colorectal cancers are one of the most prevalent tumour types worldwide and, despite the emergence of targeted and biologic therapies, have among the highest…”
Get full text

Complex refractive indices in the near-ultraviolet spectral region of biogenic secondary organic aerosol aged with ammonia by Flores, J M, Washenfelder, R A, Adler, G, Lee, H J, Segev, L, Laskin, J, Laskin, A, Nizkorodov, S A, Brown, S S, Rudich, Y

“…Atmospheric absorption by brown carbon aerosol may play an important role in global radiative forcing. Brown carbon arises from both primary and secondary…”
Get more information

1247P Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC by Kuang, S., Liu, M., Ho, C., Berthelet, E., Laskin, J., Sun, S., Zhang, T., Melosky, B.

Get full text

Sweet-type star fruit supplementation controls oxidative stress status and enhances the community walking capacity among elderly Thai by Kaju, Jynwara, Leelarungrayub, Jirakrit, Natakankitkul, Surapol, Laskin, James J

“…Sweet-type Star fruit (SF) (Averrhoa carambola L.) is seasonal and more available for purchase in many markets in Thailand, when compared to the sour-type…”
Get full text

Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment by Ramsden, K, Laskin, J, Ho, C

“…Abstract Aims Platinum-based adjuvant chemotherapy is the standard of care for resected stage II non-small cell lung cancer (NSCLC). The purpose of this…”
Get full text

Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location by Ho, C., Leung, B., Rennie, H., Laskin, J., Wu, J., Bates, A.

Get full text

Relationship Between Functional Classification Levels and Anaerobic Performance of Wheelchair Basketball Athletes by Molik, Bartosz, Laskin, James J., Kosmol, Andrzej, Skucas, Kestas, Bida, Urszula

“…Wheelchair basketball athletes are classified using the International Wheelchair Basketball Federation (IWBF) functional classification system. The purpose of…”
Get full text

Epidermal growth factor receptor: a promising target in solid tumours by Laskin, Janessa J., Sandler, Alan B.

“…The epidermal growth factor receptor (EGFR) is expressed in a wide variety of solid tumours. It has been demonstrated that the EGFR-associated signaling…”
Get full text

NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option by Weinberg, B., Renouf, D., Lim, H., Heining, C., Schlenk, R., Jones, M., Liu, S., Cseh, A., Solca, F., Laskin, J.

Get full text

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors by Titmuss, Emma, Yu, Irene S, Pleasance, Erin D, Williamson, Laura M, Mungall, Karen, Mungall, Andrew J, Renouf, Daniel J, Moore, Richard, Jones, Steven J M, Marra, Marco A, Laskin, Janessa J, Savage, Kerry J

“…Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types, and durable responses can be observed in select populations…”
Get full text